|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Following a broad panel of immunohistochemical stains, the strong positive staining of the spindle cells for LCA (CD45), CD20, and Bcl-6 confirmed the diagnosis of follicle center cell lymphoma.
|
31693188 |
2020 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Both patients were diagnosed with NMOSD and initiated on anti-CD20 agents prior to lymphoma diagnosis, though the short duration of exposure argues against a direct role.
|
31706113 |
2020 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Amplification of CD20 Cross-Linking in Rituximab-Resistant B-Lymphoma Cells Enhances Apoptosis Induction by Drug-Free Macromolecular Therapeutics.
|
29595951 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
CD20-positive T-cell lymphoma is a very rare type of lymphoma that is refractory to CHOP-like regimens alone.
|
29561444 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The obtained tumor cells exhibited typical cytological features of malignant lymphoma and were positive for CD20.
|
29725409 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Bispecific antibody (CD20-CD47SL) fusion of anti-CD20 (Rituximab) and anti-CD47 also demonstrated a synergistic effect against lymphoma in preclinical models.
|
29709247 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Using immunohistochemistry, the lymphoma cells were positive for CD3 (weak), CD20 and HHV8.
|
29105119 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Rituximab is an anti-CD20 antibody used to deplete B lymphocytes in lymphoma and autoimmune disease.
|
29561469 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We investigated combination therapy of IL-15 with rituximab in a syngeneic mouse model of lymphoma transfected with human CD20 and with alemtuzumab (Campath-1H) in a xenograft model of human adult T cell leukemia (ATL).
|
30373815 |
2018 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Age and CD20 Expression Are Significant Prognostic Factors in Human Herpes Virus-8-negative Effusion-based Lymphoma.
|
30273194 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
A phase I study of recombinant human (rh) IL-18 given with ofatumumab was undertaken in patients with CD20 lymphoma who had undergone high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
|
29517616 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In order to treat lymphoma, monoclonal antibodies (mAb) can target different antigens, including CD19, CD20 and CD22 on the surface of B-cells.
|
29922424 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
It is known for some time that the immune cell composition of the lymphoma microenvironment is important because high numbers of tissue-infiltrating macrophages correlate with poor outcome in patients receiving chemotherapy but not in patients receiving the combination of chemotherapy and CD20-specific monoclonal antibody rituximab.
|
29974035 |
2018 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Chimeric antibodies also induced ADCC against ibrutinib-resistant and rituximab-insensitive CD20-deficient variant lymphomas, respectively.
|
29180606 |
2018 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here, we report the production of an anti-cancer monoclonal antibody against the CD20 protein from egg whites of transgenic hens, and validated the bio-functional activity of the protein in B-lymphoma and B-lymphoblast cells.
|
29554481 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The results show that srtA-generated OFA-MMAE conjugate system provides a viable strategy for targeting CD20+ B lineage lymphomas.
|
27873460 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Addition of rituximab to salvage therapy before ASCT appears to improve the response rate, transplantation rate, and overall survival in patients with CD20+ lymphoma who responded to R-CHOP.
|
27266754 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The cytotoxic effects of RDMs in combination with ultrasound (RDMs+US) were evaluated in vitro in CD20+ and CD20- cell lines, and its antitumor activities were assessed in Raji (CD20+) and Jurkat (CD20-) lymphoma cell-grafted mice.
|
27902473 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
This was a single-center open-label phase II trial (NCT01686165) geared toward heavily pretreated patients with CD20-positive aNHL.
|
28869931 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Both STINGa and TLRa induced cytokine release, modulated FcγR expression, and augmented mAb-mediated tumor cell phagocytosis <i>in vitro</i> However, only STINGa reversed the suppressive FcγR profile <i>in vivo</i>, providing strong adjuvant effects to anti-CD20 mAb in murine models of lymphoma.
|
28512240 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Using a syngeneic immunocompetent mouse model, we observed that targeting lymphoma with interferon-α (IFNα) abolished resistance of B-cell lymphoma to anti-CD20 while limiting interferon (IFN)-associated systemic toxicity in the host.
|
28533311 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The in vitro tests confirmed that targeted RDMSNs could selectively adhere to the surface of lymphoma B cells via specific binding with the CD20 antigen and be internalized into CD20 positive Raji cells but few CD20 negative Jurkat cells, which leads to increased cytotoxicity and apoptosis of the DOX in Raji cells due to the release of the entrapped DOX with high efficiency in the slightly acidic intracellular microenvironment.
|
28166836 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The ability of rituximab, an anti-CD20 antibody, to suppress human lymphoproliferation from a patient's ovarian tumor in SCID mice and prevent growth of an established lymphoma led to a practice change with a goal to reduce the incidence of lymphomas.
|
28658648 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We engineered antibody fragments targeting human CD20 and studied their potential as immunoPET tracers in transgenic mice (huCD20TM) and in a murine lymphoma model expressing human CD20.<b>Experimental Design:</b> Anti-CD20 cys-diabody (cDb) and cys-minibody (cMb) based on rituximab and obinutuzumab (GA101) were radioiodinated and used for immunoPET imaging of a murine lymphoma model.
|
28928164 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
TP53 mutations are independent predictors of survival in untreated patients with aggressive CD20+ lymphoma.
|
28614910 |
2017 |